Citations

Clear

1031 citation(s) found for "Clark, AS".

Distinguishing Spastic and Dystonic Features in a Patient With a History of Brainstem Encephalitis: A Clinical Case Study
Clark, Heather M. , Clark, Heather M

Mayo Clinic

Perspectives of the ASHA Special Interest Groups | June 3, 2021 | Volume: 6 | Issue: 3 | Pages: 531-541

10.1044/2021_persp-20-00143 Get It

Purpose One role of a speech-language pathologist (SLP) is to differentially diagnose motor speech disorders to aid physicians, typically neurologists, in establishing a medical diagnosis. The present case study describes the clinical problem solving undertaken by the SLP to characterize the nature of neurological deficits to develop an appropriate management plan. Method The patient is a 29-year-old man with a history of brainstem encephalitis who presented for evaluation of dysarthria, dysphagia, and gait difficulties. The neurological exam characterized a spastic dysarthria. The SLP conducted a motor speech examination expressly for the purpose of differential diagnosis. Results The patient exhibited features of spastic dysarthria including strained phonation and hypernasality, equivocally slow rate associated with intermittent interword pauses rather than lengthened segments, and articulatory imprecision in the absence of weakness or slowness of the articulators. Defining features of spastic dysarthria absent from his speech were monopitch and monoloudness, as well as slow alternate motion rates. A diagnosis of hyperkinetic dysarthria associated with dystonia was informed by (a) hypernasality disproportionate to other deviant speech features, with preserved reflexive velar movements and nonspeech movements; (b) adventitious lip pursing; (c) modest improvement in speech with sensory tricks; (d) mild and intermittent phonatory strain; and (e) normal nonspeech oral motor function. Conclusions This case demonstrates the role speech-language pathology can play in the neurological assessment and management process. The recognition by the SLP of hyperkinetic dysarthria led to additional diagnostic tests and to a broader range of options for medical management.
Evaluation of intra-tumoral (IT) SD-101 and pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: Results from the I-SPY 2 trial.
Chien, A. Jo , Ewing, Cheryl Ann, Campbell, Michael J. , Albain, Kathy S. , Stringer-Reasor, Erica , Church, An , Clark, Amy S. , Nanda, Rita, Berry, Donald A. , Soliman, Hatem Hussein , Boughey, Judy C. , Rugo, Hope S. , Wallace, Anne M. , Kalinsky, Kevin M. , Elias, Anthony , Mitri, Zahi Ibrahim , Thomas, Alexandra , Yau, Christina , Esserman, Laura J.

Mayo Clinic

Journal of Clinical Oncology | June 1, 2021 | Volume: 39 | Issue: 15_suppl | Pages: 508-508

10.1200/jco.2021.39.15_suppl.508 Get It

508 Background: I-SPY 2 is a multicenter, phase 2 trial using response-adaptive randomization within molecular subtypes defined by receptor status and MammaPrint (MP) risk to evaluate novel agents as neoadjuvant therapy for women with high-risk breast cancer. SD-101 is an investigational Toll-like receptor 9 (TLR9) agonist CpG-C class oligodeoxynucleotide that stimulates the production of IFN-α and interleukin (IL)-12, functional maturation of plasmacytoid dendritic cells, and production of cytotoxic antibodies. IT SD-101 was combined with systemic anti-PD-1 antibody Pb to investigate the antitumor and immunologic activity of this novel immunotherapeutic strategy. Methods: Women with tumors ≥ 2.5cm were eligible for screening. Only pts (pts) with HER2- disease were eligible for this treatment. Treatment included weekly P x 12 in combination with IT SD-101 2 mg/ml (1 ml for T2 tumors, 2 ml for >T3 tumors) weekly x 4, then q3 weeks x 2, and IV Pb q3 weeks x 4, followed by doxorubicin/cyclophosphamide (AC) q2-3 weeks x 4 (SD-101+Pembro 4). Pts in the control arm received weekly P x 12 followed by AC q2-3 weeks x 4. The I-SPY 2 methods have been previously published. This investigational arm was eligible for graduation (>85% chance of success in a 300-person phase 3 neoadjuvant trial) in 3 of 10 pre-defined signatures: HER2-, hormone receptor (HR)+/HER2- and HR-/HER2-. Results: 75 pts were randomized and evaluable in SD-101+Pembro 4 treatment arm. The control arm included 329 historical controls enrolled since April 2010. The study arm was stopped due to maximal patient accrual. Pt characteristics were balanced; 56% HR+, 44% HR-. The probability that SD-101+Pembro4 was superior to control exceeded 97% for all eligible tumor signatures, but did not reach the threshold for graduation in any of the signatures. However, it is notable that the rate of pCR/Residual Cancer Burden 1 (RCB1) in the HR+/HER2- signature was 51%. Preliminary safety events for SD-101+Pembro 4 include increased rates of fever, neutropenia, febrile neutropenia, transaminitis, and immune-related events, including adrenal insufficiency. Conclusions: The SD-101+Pembro 4 regimen was active but did not meet the pre-specified threshold for graduation in I-SPY 2. pCR/RCB 1 analysis suggests improved response in the HR+/HER-negative signature compared to control. The clinical significance of these findings needs to be weighed against the potential risk of immune-related toxicities. Clinical trial information: NCT01042379. [Table: see text]
The Longitudinal Early‐onset Alzheimer's Disease Study (LEADS): Framework and methodology
Apostolova, Liana G. , Aisen, Paul , Eloyan, Ani , Fagan, Anne M. , Fargo, Keith N. , Gatsonis, Constantine , Grinberg, Lea T. , Jack, Clifford R. , Kramer, Joel H. , Kukull, Walter A. , Murray, Melissa E. , Nudelman, Kelly , Rumbaugh, Malia, Vemuri, Prashanthi , Trullinger, Amy, Iaccarino, Leonardo , Day, Gregory S. , Graff‐Radford, Neill R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Rogalskı, Emily , Salloway, Steve , Wingo, Thomas S. , Carrillo, María C. , Rabinovici, Gil D. , Jack, Clifford R , Vemuri, Prashanthi , Day, Gregory S , Murray, Melissa E , Grinberg, Lea , Rabinovici, Gil D , Nudelman, Kelly N , Wingo, Thomas S , Foroud, Tatiana , Koeppe, Robert A. , Toga, Arthur W. , Honig, Lawrence S. , Jones, David T. , Masdeu, Joseph C , Musiek, Erik , Wolk, David A. , Dickerson, Bradford Clark

Mayo Clinic

Alzheimer's & Dementia | May 21, 2021 | Volume: 17 | Issue: 12 | Pages: 2043-2055

10.1002/alz.12350 | PMID 34018654 Get It

AbstractPatients with early‐onset Alzheimer's disease (EOAD) are commonly excluded from large‐scale observational and therapeutic studies due to their young age, atypical presentation, or absence of pathogenic mutations. The goals of the Longitudinal EOAD Study (LEADS) are to (1) define the clinical, imaging, and fluid biomarker characteristics of EOAD; (2) develop sensitive cognitive and biomarker measures for future clinical and research use; and (3) establish a trial‐ready network. LEADS will follow 400 amyloid beta (Aβ)‐positive EOAD, 200 Aβ‐negative EOnonAD that meet National Institute on Aging–Alzheimer's Association (NIA‐AA) criteria for mild cognitive impairment (MCI) or AD dementia, and 100 age‐matched controls. Participants will undergo clinical and cognitive assessments, magnetic resonance imaging (MRI), [18F]Florbetaben and [18F]Flortaucipir positron emission tomography (PET), lumbar puncture, and blood draw for DNA, RNA, plasma, serum and peripheral blood mononuclear cells, and post‐mortem assessment. To develop more effective AD treatments, scientists need to understand the genetic, biological, and clinical processes involved in EOAD. LEADS will develop a public resource that will enable future planning and implementation of EOAD clinical trials.
Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease
Lai, Dongbing , Fontanillas, Pierre , Aasly, Jan , Beecham, Gary W. , Berg, Daniela , Bressman, Susan , Brockmann, Kathrin , Clark, Lorraine N. , Cookson, Mark , Das, Sayantan , Farrer, Matthew J. , Trinh, Joanne , Gasser, Thomas , Gustavsson, Emil K. , Klein, Christine , Langston, J. William, Lynch, Timothy , Marder, Karen, Martin, Eden R. , Mejia‐Santana, Helen, Molho, Eric , Nuytemans, Karen , Ozelius, Laurie J. , Raymond, Deborah , Ross, Owen A. , Samii, Ali, Saunders‐Pullman, Rachel , Schüle, Birgitt , Tolosa, Eduardo , Tomkins, James E. , Vilas, Dolores , Trojanowski, John Q. , Uitti, Ryan J. , Zabetian, Cyrus P. , Urtreger, Avi Orr, Cannon, P. F. , Fiske, Brian , Brockman, Kathrin , Klein, Christine , Ross, Owen A , Uitti, Ryan, Visanji, Naomi P , Zabetian, Cyrus P , Mirelman, Anat , Alipanahi, Babak , Schwantes-An, Tae-Hwi Linus , Alcalay, Roy N. , Brice, Alexis , Deerlin, Vivianna M. Van , Follett, Jordan , Goldwurm, Stefano , Lang, Anthony E. , Latourelle, Jeanne C. , Marras, Connie , McLean, Cory Y. , Myers, Richard H. , Payami, Haydeh , Rogaeva, Ekaterina A. , Rogers, Michael P. , Schulte, Claudia , Scott, William K. , Tanner, Caroline M. , Vance, Jeffery M. , Visanji, Naomi P. , Wszołek, Zbigniew K. , Giladi, Nir , Foroud, Tatiana

Mayo Clinic

Annals of Neurology | May 3, 2021 | Volume: 90 | Issue: 1 | Pages: 76-88

10.1002/ana.26094 | PMID 33938021 Get It

Objective The aim of this study was to search for genes/variants that modify the effect of LRRK2 mutations in terms of penetrance and age‐at‐onset of Parkinson's disease. Methods We performed the first genomewide association study of penetrance and age‐at‐onset of Parkinson's disease in LRRK2 mutation carriers (776 cases and 1,103 non‐cases at their last evaluation). Cox proportional hazard models and linear mixed models were used to identify modifiers of penetrance and age‐at‐onset of LRRK2 mutations, respectively. We also investigated whether a polygenic risk score derived from a published genomewide association study of Parkinson's disease was able to explain variability in penetrance and age‐at‐onset in LRRK2 mutation carriers. Results A variant located in the intronic region of CORO1C on chromosome 12 (rs77395454; p value = 2.5E‐08, beta = 1.27, SE = 0.23, risk allele: C) met genomewide significance for the penetrance model. Co‐immunoprecipitation analyses of LRRK2 and CORO1C supported an interaction between these 2 proteins. A region on chromosome 3, within a previously reported linkage peak for Parkinson's disease susceptibility, showed suggestive associations in both models (penetrance top variant: p value = 1.1E‐07; age‐at‐onset top variant: p value = 9.3E‐07). A polygenic risk score derived from publicly available Parkinson's disease summary statistics was a significant predictor of penetrance, but not of age‐at‐onset. Interpretation This study suggests that variants within or near CORO1C may modify the penetrance of LRRK2 mutations. In addition, common Parkinson's disease associated variants collectively increase the penetrance of LRRK2 mutations. ANN NEUROL 2021;90:82–94
Facilitating End-of-Life Interaction Between Patients With Severe Communication Impairment and Their Families
Chandregowda, Adithya , Stierwalt, Julie A. G., Clark, Heather M. , Clark, Heather M

Mayo Clinic

Perspectives of the ASHA Special Interest Groups | April 21, 2021 | Volume: 6 | Issue: 3 | Pages: 649-653

10.1044/2021_persp-20-00282 Get It

Purpose The purpose of this report is to promote conversation among medical speech-language pathologists (SLPs) about their role in facilitating family–patient interaction involving patients who acutely encounter the end-of-life (EOL) phase and have severe communication impairment. Case Report We provide self-reflections from our own clinical practice, pertinent literature review, and medical chart review of a relevant patient to serve as a catalyst for such discussion. Reflections We share a preliminary handout containing strategies that SLPs could provide family members of patients who have encountered an EOL phase and have severe communication impairment (e.g., global aphasia) and reduced alertness level. Clinical Implications SLPs can play an important role in facilitating EOL patient–family interaction and alleviate suffering even when patients have severe communication impairment.
National trends in prescription drug expenditures and projections for 2021
Tichy, Eric M. , Hoffman, James M. , Suda, Katie J. , Rim, Matthew H, Tadrous, Mina , Cuéllar, Sandra , Clark, John Spencer , Wiest, Michelle D., Matusiak, Linda M., Schumock, Glen T.

Mayo Clinic

American Journal of Health-System Pharmacy | April 21, 2021 | Volume: 78 | Issue: 14 | Pages: 1294-1308

10.1093/ajhp/zxab160 | PMID 33880494 Get It

Abstract Purpose To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2021 in the United States, with a focus on the nonfederal hospital and clinic sectors. Methods Historical patterns were assessed by examining data on drug purchases from manufacturers using the IQVIA National Sales Perspectives database. Factors that may influence drug spending in hospitals and clinics in 2021 were reviewed—including new drug approvals, patent expirations, and potential new policies or legislation. Focused analyses were conducted for biosimilars, cancer drugs, generics, coronavirus disease 2019 (COVID-19) pandemic influence, and specialty drugs. For nonfederal hospitals, clinics, and overall (all sectors), estimates of growth of pharmaceutical expenditures in 2021 were based on a combination of quantitative analyses and expert opinion. Results In 2020, overall pharmaceutical expenditures in the United States grew 4.9% compared to 2019, for a total of $535.3 billion. Utilization (a 2.9% increase) and new drugs (a 1.8% increase) drove this increase, with price changes having minimal influence (a 0.3% increase). Adalimumab was the top drug in 2020, followed by apixaban and insulin glargine. Drug expenditures were $35.3 billion (a 4.6% decrease) and $98.4 billion (an 8.1% increase) in nonfederal hospitals and clinics, respectively. In clinics, growth was driven by new products and increased utilization, whereas in hospitals the decrease in expenditures was driven by reduced utilization. Several new drugs that will influence spending are expected to be approved in 2021. Specialty and cancer drugs will continue to drive expenditures along with the evolution of the COVID-19 pandemic. Conclusion For 2021, we expect overall prescription drug spending to rise by 4% to 6%, whereas in clinics and hospitals we anticipate increases of 7% to 9% and 3% to 5%, respectively, compared to 2020. These national estimates of future pharmaceutical expenditure growth may not be representative of any particular health system because of the myriad of local factors that influence actual spending.
Efficacy and Safety of Endoscopic Balloon Placement for Weight Loss in Patients With Cirrhosis Awaiting Liver Transplantation
Watt, Kymberly D. , Rizk, Monika, Jaruvongvanich, Pete, Sánchez, William , Venkatesh, Sudhakar K. , Bamlet, Heather , Tiedtke, Kathryn, Malhi, Harmeet , Grothe, Karen, Clark, Matthew M. , Venkatesh, Sudhakar K , Malhi, Harmeet , Acosta Cardenas, Andres, Sanchez, William , Heimbach, Julie K. , Port, John D. , Cárdenas, Andrés , Mundi, Manpreet S. , Dayyeh, Barham K. Abu

Mayo Clinic

Liver Transplantation | April 18, 2021 | Volume: 27 | Issue: 9 | Pages: 1239-1247

10.1002/lt.26074 | PMID 33866660 Get It

The efficacy and safety of a fluid‐filled intragastric balloon (IGB) for weight loss in patients with cirrhosis on the liver transplantation (LT) waiting list is unknown. We enrolled stable compensated patients with body mass index >35 kg/m2 and on the waiting list for IGB placement endoscopically for a maximum of 6 months. A total of 8 patients (7 men) aged mean ± SD, 56 ± 4.6 years with Model for End‐Stage Liver Disease–sodium (MELD‐Na) scores 14.1 ± 3.4 experienced weight reduction (146 ± 22.2 kg versus 127 ± 21.6 kg [P = 0.005] with IGB in place and 130 ± 24.6 kg [P = 0.014] at 6 months), with a total body weight loss of 12.2% ± 8.8% with IGBs in place and 10.9% ± 8.9% at 6 months. Body fat decreased from 48.6% ± 5.8% to 40.6% ± 6.4% (P = 0.001) and lean mass increased from 51.3% ± 6% to 59.4% ± 6.4% (P = 0.001). No change in MELD‐Na scores occurred (P = 0.770). Early balloon retrieval was attributed to accommodative symptoms (n = 2) and liver decompensation (n = 1). Mallory Weiss tears (n = 3), but no portal hypertensive bleeding, occurred. Liver decompensation and/or hepatocellular carcinoma (HCC) developed in 3 patients. A total of 4 patients with LT ± sleeve gastrectomy maintained overall weight loss. Of 4 patients who did not receive transplants, 2 experienced weight regain. IGB results in short‐term weight loss in patients with cirrhosis awaiting LT, with body fat loss without lean mass loss. Adverse effects were common. Decompensation and HCC did occur, with uncertainty of the relation to weight loss, and thus careful patient selection and close follow‐up are required.
Assessment of Cumulative Incidence and Severity of Primary Open-Angle Glaucoma Among Participants in the Ocular Hypertension Treatment Study After 20 Years of Follow-up
Heuer, Dale K. , Higginbotham, Eve J. , Parrish, Richard , Khanna, Cheryl L. , Brandt, James D. , Soltau, Joern B., Keltner, John L., Huecker, Julia B., Wilson, Bradley , Gordon, Mae O. , Group, Ocular Hypertension Study, Gedee, Steven J., Esquiabro, Maria, Fabrizio, Matthew J., Patorgis, Charles J., Long, Teresa A., McManus, Paul E., Washington, Chantura, Chang, Peter , Orengo-Nania, Silvia, Leger, April, Kinast, Robert M. , Jones, Emily P., Goldman, Casie, Beck, Allen D. , Costarides, Anastasios P., Leef, Donna, Imami, Nauman R., Darnley-Fisch, Deborah , Crandall, David, Gutkowski, Melanie, Hall, Julianne, Fantin, Aldo, Wells, Judy, Jampel, Henry , Quigley, Harry A., Miller, Rhonda, Kalarn, Sachin , Coleman, Anne L. , Young, Jonathan W., Peterson, Christine A., Giaconi, JoAnn A. , Law, Simon K., Duarte, Pamela B., Wood, Sarah Dougherty , Moroi, Sayoki, Gilbert, Jesse L., Shukairy, Aman, Juzych, Mark S. , Milanovic, Cheryl, O'Grady, John M., Conett, Linda A. Van, Mohay-Ambrus, Judith, Bottorff, Michelle, Bennett, Jeffrey R., Sultze, Jane L., Patel, Dharmendra, Cobb, Steven H., Bhattacharjee, Pompa, Cioffi, George A., Blumberg, Dana M., Moraes, Carlos Gustavo De , Atakulova, Marzhan, Weber, Paul A., Sawchyn, Andrea K., Williams, Demarcus, Bennett, George, Bennett, Lindsay C., Miller-Ellis, Eydie , Sankar, Prithvi S. , Grand-Drossner, Sheri, Piltz‐Seymour, Jody R., Niemczyk, Jane L., Brandt, James D., Lim, Michelle, Balasubramaniam, Saranya C., Baik, Annie K., Arnold, Marisa S., Slight, J. Rigby, Ou, Yvonne , Lamping, Kathleen A., Vitelli, Cheryl L., Ashburn, Frank S., Hardney, Karen S., Schwartz, Arthur L., Weiss, Howard S., Clark, Clete, Bhorade, Anjali M., Lind, John T., Adcock, Eve, Plumb, Kim, Leming, Laura, Dillon, B A, Palmberg, Paul, Hodapp, Elizabeth, Varner, Elizabeth A., Savatovsky, Eleonore , Vandenbroucke, Ruth, Dirkes, Keri , Vega, Suzanne , Hunsicker, Maria, Proudfoot, J. , Dunn, D, Everett, Donald F., Gutowski, Melanie, Fischbach, Ellen, Clark, Karen A., Morris, Patricia A., Quinn, Melanie, Pistorius, Sam, Haertter, Leonard W., Kass, Michael A. , Johnson, Chris A. , Liu, Lei , Miller, J. Philip , Quigley, Harry A. , Group, Ocular Hypertension Study, Patorgis, Charles J., Washington, Chantura, Mansberger, Steven L. , Wells, Judy, Quigley, Harry A., Saeedi, Osamah J. , Hughes, Bret A. , Liebmann, Jeffrey M. , Al‐Aswad, Lama A. , Brandt, James D., Lim, Michelle C., Weinreb, Robert Neal , Smith, Mike A., Feuer, William J. , Zangwill, Linda M. , Morris, Patricia A.

Mayo Clinic

JAMA Ophthalmology | April 17, 2021 | Volume: 139 | Issue: 5 | Pages: 558

10.1001/jamaophthalmol.2021.0341 | PMID 33856434 Get It

The Importance of Conceptualizing and Defining Episodes of Lucidity
Block, Laura , Benson, Clark , Griffin, Joan M. , Gilmore‐Bykovskyi, Andrea L

Mayo Clinic

Journal of Gerontological Nursing | April 9, 2021 | Volume: 47 | Issue: 4 | Pages: 5-5

10.3928/00989134-20210326-01 | PMID 34038253 Get It